A recent research report published by MarkNtel Advisors, the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market is expected to register around 9.5% CAGR during 2022-27. The rapidly increasing prevalence of cancer, including HNSCC, across different countries in the world, i.e., accelerating the demand for more & more accurate diagnosis & effective treatment.
Governments of different countries are substantially investing in various research & development activities associated with the HNSCC and laying out favorable policies for the leading biopharma companies to conduct clinical trials of medications.
With smoking, alcohol consumption, Human Papillomavirus (HPV) infection, etc., as the prominent causes of HNSCC, there are various ongoing campaigns for spreading awareness among people about the ill effects of these causes and the availability of diagnosis & treatment like chemotherapy & immunotherapy for HNSCC.
As a result, there is a massive influx of HNSCC patients undergoing diagnoses & seeking treatments. Numerous cancer research institutes are rigorously working on developing more effective therapeutics to cater to the high unmet patient needs and, in turn, augmenting the growth of the global market, further states the research report, “Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market Analysis, 2022.”
Emerging Trends of Combined Modality Therapy to Boost the Global Market
Chemotherapy is the most opted treatment by patients with Head and Neck Squamous Cell Carcinoma, owing to its ability to be combined with other therapies. In the case of advanced HNSCC, multiple modality therapy is the ideal treatment, wherein chemotherapy is combined with surgery, radiation therapy, etc., depending on the patient's health condition.
Usually, surgery, followed by chemotherapy & radiation therapy, provides higher efficacy & safety. In addition, chemotherapy in combination with radiation therapy using palliative care has shown positive outcomes in the treatment of metastatic cancer sites. Hence, these aspects are promulgating the overall growth of the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market for chemotherapy as the treatment.
With Massive Patient Pool & Healthcare Expenditure, Asia-Pacific to Dominate the Market
Asia-Pacific is expecting the largest share in the Head and Neck Squamous Cell Carcinoma (HNSCC) Market globally during 2022-27. It attributes principally to the mounting cases of HNSCC across China, India, Australia, & Southeast Asia, coupled with the growing government focus on expanding the healthcare infrastructure and presenting favorable policies to biopharma firms for conducting rapid clinical trials of novel therapies for HNSCC treatment in order to cater to the unmet needs of patients.
Besides, the massive patient pool for HNSCC across Asia-Pacific is soaring the demand for more effective & affordable diagnosis & treatment at healthcare facilities. It, in turn, is instigating the industry players to increase the production & distribution capacities and propelling governments to increase their procurement abilities, thereby propelling the growth of the Asia-Pacific Head and Neck Squamous Cell Carcinoma (HNSCC) Market.
The major companies in the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market include AbbVie Inc., AstraZeneca PLC, Amgen Inc., Bayer AG, Bristol Myers Squibb, DFG Oncology, Dr. Reddy’s Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche AG, Jiangsu Hengrui, Merck & Co., Inc., Novartis International AG, Pfizer Inc., and Sanofi S.A.
Key Questions Answered in the Research Report